1. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2. Issue 3 (13th November 2021) Authors: Walker, Lauren E.; FitzGerald, Richard; Saunders, Geoffrey; Lyon, Rebecca; Fisher, Michael; Martin, Karen; Eberhart, Izabela; Woods, Christie; Ewings, Sean; Hale, Colin; Rajoli, Rajith K. R.; Else, Laura; Dilly‐Penchala, Sujan; Amara, Alieu; Lalloo, David G.; Jacobs, Michael; Pertinez, Henry; Hat... Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 3(2022) Page Start: 585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cerebrospinal fluid exposure of cenicriviroc in HIV‐positive individuals with cognitive impairment. Issue 5 (4th March 2019) Authors: Alagaratnam, Jasmini; Dilly‐Penchala, Sujan; Challenger, Elizabeth; Else, Laura; Legg, Ken; Petersen, Claire; Jones, Brynmor; Kulasegaram, Ranjababu; Seyedkazemi, Star; Lefebvre, Eric; Khoo, Saye; Winston, Alan Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 5(2019) Page Start: 1039 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗